摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(4-methanesulfonylphenyl)-6-methyl-3-(4-methylphenoxy) pyran-4-one

中文名称
——
中文别名
——
英文名称
2-(4-methanesulfonylphenyl)-6-methyl-3-(4-methylphenoxy) pyran-4-one
英文别名
2-(4-methanesulfonylphenyl)-6-methyl-3-(4-methylphenoxy)-pyran-4-one;2-(4-methanesulfonylphenyl)-6-methyl-3-(4-methylphenoxy)pyran-4-one;2-(4-Methanesulfonyl-phenyl)-6-methyl-3-p-tolyloxy-pyran-4-one;6-methyl-3-(4-methylphenoxy)-2-(4-methylsulfonylphenyl)pyran-4-one
2-(4-methanesulfonylphenyl)-6-methyl-3-(4-methylphenoxy) pyran-4-one化学式
CAS
——
化学式
C20H18O5S
mdl
——
分子量
370.426
InChiKey
RDDACGGTEDFKEE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.5
  • 重原子数:
    26
  • 可旋转键数:
    4
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.15
  • 拓扑面积:
    78
  • 氢给体数:
    0
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    4-甲基硫代-2-溴苯乙酮 在 PPA 、 四丁基硫酸氢铵 、 palladium diacetate 、 potassium carbonate 、 magnesium monoperoxyphthalate hexahydrate 、 三乙胺三(邻甲基苯基)磷 作用下, 以 甲醇二氯甲烷N,N-二甲基甲酰胺 为溶剂, 反应 120.0h, 生成 2-(4-methanesulfonylphenyl)-6-methyl-3-(4-methylphenoxy) pyran-4-one
    参考文献:
    名称:
    Synthesis and Biological Evaluation of 2-Phenylpyran-4-ones:  A New Class of Orally Active Cyclooxygenase-2 Inhibitors
    摘要:
    A series of 2-phenylpyran-4-ones were prepared and evaluated for their ability to inhibit cyclooxygenase-2 (COX-2). Extensive structure-activity relationship work was carried out within this series, and a number of potent and selective COX-2 inhibitors were identified. Compounds having a p-methylsulfone group at the 2-phenyl ring showed the best COX-2 inhibitory activity. The introduction of a substituted phenoxy ring at position 3 enhanced both the in vitro and in vivo activity within the series. A selected group of 3-phenoxypyran-4-ones exhibited excellent activity in an experimental model of pyresis. The in vivo antiinflammatory activity of these compounds was confirmed with the evaluation of their antiarthritic and analgesic effectiveness. Moreover, their pharmacokinetic profile in rats is compatible with a once a day administration by oral route in humans. Within this novel series, compounds 21, 31, 34, and 35 have been selected for further preclinical. and clinical evaluation.
    DOI:
    10.1021/jm049882t
点击查看最新优质反应信息

文献信息

  • Combination of a Cox-2 inhibitor and a DNA topoisomerase I inhibitor for treatment of neoplasia
    申请人:Masferrer L. Jaime
    公开号:US20050187172A1
    公开(公告)日:2005-08-25
    The present invention provides combinations of a Cox-2 inhibitor and a DNA topoisomerase inhibitor and methods of use thereof for preventing and/or treating neoplasia or or a neoplasia-related disorder in a subject.
    本发明提供了一种COX-2抑制剂和DNA拓扑异构酶抑制剂的组合物,以及它们的使用方法,用于预防和/或治疗受试者中的肿瘤或与肿瘤相关的疾病。
  • Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
    申请人:Pulaski P. Steven
    公开号:US20050014729A1
    公开(公告)日:2005-01-20
    A method for preventing or treating dermatological disorders and dermatological disorder-related complications in a subject involves a monotherapy with a Cox-2 inhibitor or a combination therapy with a Cox-2 inhibitor and a dermatological treatment agent. Also described are therapeutic compositions comprising a Cox-2 inhibitor and a dermatological treatment agent. Pharmaceutical compositions and kits for implementing the present method are also described.
    一种预防或治疗受试者的皮肤病和与皮肤病相关并发症的方法涉及使用Cox-2抑制剂进行单独治疗或与Cox-2抑制剂和皮肤治疗剂的联合治疗。还描述了包含Cox-2抑制剂和皮肤治疗剂的治疗组合物。还描述了用于实施本方法的药物组合物和工具包。
  • Treatment and prevention of otic disorders with Cox-2 inhibitors alone or in combination with otic agents
    申请人:Pharmacia Corporation
    公开号:US20040204471A1
    公开(公告)日:2004-10-14
    A method for preventing or treating otic disorders and otic disorder-related complications in a subject involves a monotherapy with a Cox-2 inhibitor or a combination therapy with a Cox-2 inhibitor and an otic agent. Also described are therapeutic compositions comprising a Cox-2 inhibitor and an otic agent. Pharmaceutical compositions and kits for implementing the present method are also described.
    一种用于预防或治疗主体的耳部疾病和耳部疾病相关并发症的方法涉及使用Cox-2抑制剂进行单一疗法或使用Cox-2抑制剂和耳部药剂进行联合疗法。还描述了包含Cox-2抑制剂和耳部药剂的治疗组合物。还描述了用于实施本方法的药物组合物和工具包。
  • Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
    申请人:Pharmacia Corporation
    公开号:US20040220155A1
    公开(公告)日:2004-11-04
    A method is described for providing a steroid-sparing benefit to a subject that is in need of, or that is presently receiving, a corticosteroid, the method comprising administering to the subject a cyclooxygenase-2 inhibitor in combination with a corticosteroid. Therapeutic compositions, pharmaceutical compositions and kits that are useful for implementing the present method are also described.
    描述了一种为需要或目前正在接受皮质类固醇治疗的受试者提供节约类固醇的方法,该方法包括向受试者同时给予环氧合酶-2抑制剂和皮质类固醇。还描述了用于实施该方法的治疗组合物、药物组合物和工具包。
  • Method and compositions for the treatment and prevention of pain and inflammation
    申请人:Pulaski P. Steven
    公开号:US20050101563A1
    公开(公告)日:2005-05-12
    A method of preventing or treating pain or inflammation in a subject is provided by administering to the subject a Cox-2 inhibitor and a polyunsaturated fatty acid, or a prodrug thereof, wherein the amount of a Cox-2 inhibitor and polyunsaturated fatty acid or a pharmaceutically acceptable salt or prodrug thereof together constitute a pain or inflammation suppressing treatment or prevention effective amount. Glucosamine and/or chondroitin can optionally be present. Therapeutic compositions that contain the combination of Cox-2 inhibitor and polyunsaturated fatty acid and, optionally, the glucosamine and/or chondroitin, are disclosed, as are pharmaceutical compositions.
    本方法提供了一种预防或治疗受试者疼痛或炎症的方法,通过向受试者施用Cox-2抑制剂和多不饱和脂肪酸,或其前药,其中Cox-2抑制剂和多不饱和脂肪酸或其药用盐或前药的数量共同构成疼痛或炎症抑制治疗或预防有效量。可选择添加葡萄糖胺和/或软骨素。公开了包含Cox-2抑制剂和多不饱和脂肪酸以及可选的葡萄糖胺和/或软骨素的治疗组合,以及药用组合物。
查看更多